Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Verdinexor (KPT-335) 是一种特异性 XPO1/CRM1 抑制剂,具有口服生物利用度。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 547 | 现货 | ||
2 mg | ¥ 783 | 现货 | ||
5 mg | ¥ 1,320 | 现货 | ||
10 mg | ¥ 1,990 | 现货 | ||
25 mg | ¥ 3,750 | 现货 | ||
50 mg | ¥ 5,890 | 现货 | ||
100 mg | ¥ 7,930 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,280 | 现货 |
产品描述 | Verdinexor (KPT-335) (KPT-335), a specific XPO1/CRM1 inhibitor, are orally bioavailable. |
体外活性 | 在常染色体显性多囊肾疾病模型中,腹腔注射Verdinexor(5 mg/kg), 通过抑制XPO1减弱囊肿生长.每天两次口服Verdinexor(25 mg/kg)能够降低与致死性甲型流感A病毒相关的肺疾病的发病率和死亡率,主要通过降低肺中促炎性细胞因子的表达,从而减少肺病毒滴度,因此产生抗病毒活性. |
体内活性 | In Jurkat,OCI-Ly3,OCI-Ly10,和CLBL1 cells,Verdinexor inhibited cell viability with IC50 of 0.3 nM, 2.1 nM, 41.8 nM, and 8.5 nM, respectively. In Primary Canine DLBCL Cells and CLBL1 expressed XPO1 and SINE, KPT-335 induces apoptosis. Verdinexorpotently inhibits a variety of influenza virus strains, including the H1N1 epidemic virus, the highly pathogenic H5N1 bird flu virus, and the recently emerging H7N9 strain. |
细胞实验 | Cell viability for lymphoid lines is determined by the MTS assay using CellTiter 96? AQueous One Solution Cell Proliferation Assay Kit. Briefly, for lymphoid cell lines, 5×104 cells (or 1×105 primary DLBCL cells) are cultured in 100 μL of complete medium in 96-well plates in the presence of SINE compounds. After 72 hours, 20 μL of MTS solution is added to each well and cells are incubated for another 4 hours before measuring absorbance at 490 nm using a Wallac Victor 1420 Multilabel Counter. The IC50 of SINE is calculated using Prism 6 software. For the non-lymphoid cell lines, 96 well plates are seeded in triplicate in 90 μL with 2500 cells/well of OSA16, 5000 cells/well of C2, and 2500 cells/well of 323610-3. Seeded plates are cultured overnight then treated the following day with 10 μL of KPT-214 in C10 media at concentrations of 0.0001, 0.01, 0.1, 1.0, and 10 μM. Plates are collected at 92 hours, centrifuged at 1300 rpm, and supernatant is removed by inverting plates on absorbent paper. Plates are then sealed and immediately placed at ?80°C for a minimum of 12 hours. Plates are then thawed and CyQUANT ?Cell Proliferation Assay is performed following the manufacturer's protocol. Briefly, 200 μL of the diluted working CyQUANT solution is added to each well and protected from light. Fluorescence is the measured using a SpectraMax M2 microplate reader at 480 nm excitation and 520 nm emission. Results are represented as percent of control, or plotted to calculate IC50 values at 92 hours.(Only for Reference) |
别名 | KPT-335 |
分子量 | 442.32 |
分子式 | C18H12F6N6O |
CAS No. | 1392136-43-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 82 mg/mL (185.4 mM)
Ethanol: 9 mg/mL (20.3 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 2.2608 mL | 11.304 mL | 22.6081 mL | 56.5202 mL |
5 mM | 0.4522 mL | 2.2608 mL | 4.5216 mL | 11.304 mL | |
10 mM | 0.2261 mL | 1.1304 mL | 2.2608 mL | 5.652 mL | |
20 mM | 0.113 mL | 0.5652 mL | 1.1304 mL | 2.826 mL | |
DMSO | 50 mM | 0.0452 mL | 0.2261 mL | 0.4522 mL | 1.1304 mL |
100 mM | 0.0226 mL | 0.113 mL | 0.2261 mL | 0.5652 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Verdinexor 1392136-43-4 Membrane transporter/Ion channel CRM1 KPT-335 KPT 335 KPT335 Inhibitor inhibitor inhibit